BridgeBio Pharma, Inc.
BBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $221,902 | $9,303 | $77,648 | $69,716 |
| % Growth | 2,285.3% | -88% | 11.4% | – |
| Cost of Goods Sold | $3,878 | $2,446 | $3,434 | $3,114 |
| Gross Profit | $218,024 | $6,857 | $74,214 | $66,602 |
| % Margin | 98.3% | 73.7% | 95.6% | 95.5% |
| R&D Expenses | $506,461 | $455,711 | $399,462 | $451,024 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $288,931 | $150,590 | $143,189 | $192,210 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $15,605 | $7,926 | $43,765 | $0 |
| Operating Expenses | $810,997 | $614,227 | $586,416 | $643,234 |
| Operating Income | -$592,973 | -$607,370 | -$512,202 | -$576,632 |
| % Margin | -267.2% | -6,528.8% | -659.6% | -827.1% |
| Other Income/Exp. Net | $50,779 | -$45,881 | $27,550 | -$9,822 |
| Pre-Tax Income | -$542,194 | -$653,251 | -$484,652 | -$586,454 |
| Tax Expense | $1,153 | $0 | $0 | $0 |
| Net Income | -$535,762 | -$643,202 | -$481,183 | -$562,539 |
| % Margin | -241.4% | -6,913.9% | -619.7% | -806.9% |
| EPS | -2.88 | -3.95 | -3.35 | -4.43 |
| % Growth | 27.1% | -17.9% | 24.4% | – |
| EPS Diluted | -2.88 | -3.95 | -3.35 | -4.43 |
| Weighted Avg Shares Out | 186,076 | 162,792 | 147,473 | 144,357 |
| Weighted Avg Shares Out Dil | 186,076 | 162,792 | 147,473 | 144,357 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17,249 | $18,038 | $7,542 | $1,133 |
| Interest Expense | $99,290 | $81,289 | $80,438 | $46,778 |
| Depreciation & Amortization | $6,075 | $6,494 | $6,771 | $5,843 |
| EBITDA | -$436,829 | -$565,468 | -$397,443 | -$533,833 |
| % Margin | -196.9% | -6,078.3% | -511.9% | -765.7% |